Already widely considered a standard first-line treatment in older adults with mantle cell lymphoma (MCL), a Bruton tyrosine kinase inhibitor was noninferior to cytotoxic chemotherapy as front-line therapy for younger patients with MCL in the multicenter TRIANGLE trial.
The trial “clearly demonstrated that the current standard high-dose regimen is not superior to the new ibrutinib-containing regimen, even without ASCT [autologous stem cell transplant],” said Martin Dreyling,